SCHEMBL5345352

SCHEMBL5345352

CCC1CCN(CCCc2nsc3ccccc23)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.58
HTR1A P08908 7/20 0.43
DRD2 P14416 7/20 0.43
DRD3 P35462 6/20 0.43
HTR2A P28223 6/20 0.43
SLC6A4 P31645 2/20 0.42
LMNA P02545 1/20 0.42
CHRM2 P08172 1/20 0.42
ADRA2A P08913 1/20 0.42
CHRM1 P11229 1/20 0.42
DRD1 P21728 1/20 0.42
TBXA2R P21731 1/20 0.42
SLC6A2 P23975 1/20 0.42
ADRA1A P35348 1/20 0.42
OPRM1 P35372 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KCNH2 Q12809 1/20 0.42
HRH3 Q9Y5N1 1/20 0.41
HTR7 P34969 1/20 0.40
HTR6 P50406 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5331281 0.91 ACHE (0.61) ACHEHTR1ADRD2DRD3HTR2A
SCHEMBL5331835 0.90 ACHE (0.60) ACHEHTR1ADRD2DRD3HTR2A
SCHEMBL5332521 0.88 ACHE (0.54) ACHEHTR1ADRD3SLC6A4LMNA
SCHEMBL5332597 0.78 PARP1 (0.47) ACHEHTR1ADRD2SLC6A4KCNH2
SCHEMBL28814086 0.77 ACHE (0.80) ACHEKCNH2HRH3
SCHEMBL476295 0.74 MAPT (0.44) ACHEHRH3
SCHEMBL222028 0.73 ACHE (1.00) ACHEHRH3
SCHEMBL5332735 0.73 DRD3 (0.64) HTR1ADRD2DRD3HTR2ASLC6A4
SCHEMBL24762108 0.73 SIGMAR1 (0.68) KCNH2HRH3
SCHEMBL28856577 0.71 ACHE (0.42) ACHELMNAKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1535912-A1 Muscarinic agonists Arcadia Pharmaceuticals Inc. (US) 2005-06-01 EP claimed
US-20070155795-A1 MUSCARINIC AGONISTS ACADIA PHARMACEUTICALS INC. (US) 2007-07-05 US disclosed
US-7238713-B2 Muscarinic agonists ACADIA PHARMACEUTICALS, INC. (US) 2007-07-03 US disclosed
EP-1535912-A1 Muscarinic agonists Arcadia Pharmaceuticals Inc. (US) 2005-06-01 EP disclosed
US-20050113357-A1 Muscarinic agonists ANDERSON CARL-MAGNUS A (DK) 2005-05-26 US disclosed
US-6627645-B2 Cholinergic agents ACADIA PHARMACEUTICALS, INC. 2003-09-30 US disclosed
US-20020037886-A1 Muscarinic agonists ACADIA PHARMACEUTICALS INC. 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037886-A1 Muscarinic agonists CHRM2, CHRM1, CHRM4 ACHE 22/4885HTR1A 118/4885DRD2 476/4885
US-20070155795-A1 MUSCARINIC AGONISTS CHRM2, CHRM1, CHRM4 ACHE 22/4885HTR1A 118/4885DRD2 476/4885
US-20050113357-A1 Muscarinic agonists CHRM2, CHRM1, CHRM4 ACHE 22/4885HTR1A 118/4885DRD2 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.